Specialist Cardiac Safety Screening

High-quality cardiac safety screening services, including GLP hERG and CiPA assays

CONTACT US

Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds

Ion channel assays:

Cardiac ion channel profiling

  • Assessment of core cardiac ion channels: hERG, NaV1.5 and CaV1.2
  • Expanded CiPA cardiac panel: hERG, NaV1.5 (late current), CaV1.2, Kir2.1, KV4.3_KChIP and KV7.1_MinK
  • Additional cardiac channels: HCN4 and KV1.5
  • Read about CiPA screening and hERG screening

GLP hERG testing

  • GLP hERG profiling to support Investigational New Drug (IND) applications
  • Performed in accordance with current ICH S7B guidelines
  • Read about GLP hERG testing

hiPSC cardiomyocyte assays:

hiPSC cardiomyocyte assay for early cardiac de-risking

  • High throughput/high resolution assessment of compound effects on action potential morphology using voltage dye
  • Predicts free compound exposure associated with 10ms change in clinical QTc following both acute (30 min)and chronic (24 h) treatment
  • Defines probability of clinical QRS liability
  • Aligns with current ICH S7B guidelines
  • Read about our clinically translatable hiPSC cardiomyocyte assay for early cardiac derisking

hiPSC cardiomyocyte current clamp profiling

hiPSC cardiomyocyte toxicity testing

Cardiac safety ion channel experts

  • Cardiac safety team led by expert with 25 years experience in drug discovery and in vitro safety pharmacology within the pharmaceutical industry - see our Leadership Team.
  • Exceptional ion channel electrophysiology and drug discovery expertise.
  • A team of experienced cell biologists to create novel cell lines.
  • High quality, cost-effective compound screening.
  • Detailed characterisation of lead compounds in a range of high-quality assays.
  • Translational services including confirmation of efficacy in stem cell and other phenotypic models.
  • Flexible approach that best suits your project and budget.
  • Rapid turn-around times, reporting and data interpretation by highly experienced ion channel scientists.

Our expertise in GLP hERG screening is demonstrated in the case study GLP hERG Assay Validation Following ICH E14/S7B 2022 Q&A Best Practice Guidelines.

Top: Example traces in vehicle, dofetilide and E-4031. Bottom: Corresponding IT plot. IC50 values generated were within 2-fold of the values reported in the ICH E14/S7B training material. Read more about GLP hERG assay validation.

Webinar recordings

Cardiac Safety Screening Resource Library
Application of a High-Throughput Human Stem Cell Cardiomyocyte Assay for Predicting Drug-Induced Changes in ECG Parameters During Drug Discovery and Development

Understanding cardiac safety early is critical in drug development. In their latest poster, Jazz Pharmaceuticals, explain how they utilised Metrion’s clinically translatable cardiotoxicity assay to do exactly that.

Early In Vitro Preclinical Cardiovascular Safety Assessment for Smarter Drug Discovery

Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.

VIEW ALL RESOURCES
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram